Abstract
Warfarin is an anticoagulant that's broadly used in the treatment and prevention of thrombosis, in the treatment of dilated cardiomyopathy, mechanical valves, pulmonary embolism and atrial fibrillation. Amiodarone was initially introduced as an anti-anginal drug over 40 years ago but is now used therapeutically as a Class III antiarrhythmic agent. Amiodarone is associated with adverse effects like pulmonary toxicity, hepatotoxicity and thyroid disorder. There have been reviews of unfavorable drug interactions when amiodarone is administered together with a wide range of different therapeutic agents like theophylline and flecainide . However, the most common, probably the maximum risky drug interaction that amiodarone exhibits is its potentiation of the anticoagulant effect of warfarin, which substantially increases the patient’s risk of hemorrhage. Polymorphisms in cytochrome P450 genes and drug interactions are accountable for most of the warfarin toxicity. Each person is different in their susceptibity to drugs. Here we report a case in our article, which is an example of one such interaction of warfarin with amiodarone.
Keywords: Warfarin, Amiodarone.
References
- Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines Chest 2008;133 (6 Suppl):160S-198S.
- Makris M., Watson H.G. The management of coumarin-induced over-anticoagulation Annotation. J. Haematol. 2001;114:271–280.
- Hirsh J., Bates S.M. Clinical trials that have influenced the treatment of venous thromboembolism: A historical perspective. Intern. Med. 2001; 134:409-417.
- Hirsh J., Dalen J., Anderson D.R., Poller L., Bussey H., Ansell J., Deykin D. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. 2001;119:8S-21S.
- Jones D.R., Kim S.Y., Guderyon M., Yun C.H., Moran J.H., Miller G.P. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem. Res. Toxicol. 2010; 23:939-945.
- Kamali F., Wynne H. Pharmaco-genetics of warfarin. Annu. Rev. Med. 2010; 61: 63–75.
- Kaminsky L.S., Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacology. 1997;73:67-74.
- Adcock D.M., Koftan C., Crisan D., Kiechle F.L. Effect of polymorphisms in the cytochrome P450 CYP2C9 gene on warfarin anticoagulation. Pathol. Lab. Med. 2004;128:1360-1363.
- V V Pillay-modern medical toxicology chap 24 pg:334.
- Kerin NZ, Blevins RD, Goldman L, et. al. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 1988;148(8):1779-1781.
- Sanoski CA, Bauman JL. Clinical observations with the amiodarone/ warfarin interaction. Chest. 2002; 121(1):19-23.
- Hamer A, Peter T, Mandel WJ, et al. The potentiation of warfarin anticoagulation by amiodarone. Circulation. 1982;65(5):1025-1029
Corresponding Author
Dr M. Ajeeth Fera
Post Graduate, Department of Medicine,
RMMCH, Chidambaram-608002,Tamilnadu
DOI: https://dx.doi.org/10.18535/jmscr/v5i10.128
